Video Preview
🎧 Part I Podcast free on Apple Podcasts and Spotify.
🎧 Part II Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
The list, in one breath
Fifteen names, four business models, zero surprises
Hospitals: the Frist family and the unfashionable genius of owning beds
Distribution: Medline, Kinray, and the boring middle that eats everyone’s lunch
Devices: Stryker, Cook, Arthrex, and the compounding power of a titanium screw
Biotech and the picks-and-shovels crowd: Duggan, Soon-Shiong, Li Ge, Troendle
The lone software guy: Keith Dunleavy and Inovalon
Who is missing, and why that matters more than who is on it
The methodology footnote nobody reads but everybody should
What this means if you build, invest, or sell in healthcare
Abstract
Forbes dropped the 2026 Forbes 400 on Sept 15; net worths as of Sept 4. Fifteen of the 400 made their money primarily in healthcare, per Becker’s cut of the list.
Combined, the 15 are worth roughly $136B. Tom Frist Jr. and family (HCA) lead at $33.6B, followed by Robert Duggan (Summit Therapeutics) at $13.4B and Charlie Mills (Medline) at $11B.
The list breaks cleanly into four buckets: hospitals (1), distribution and supply (5), medical devices (5), and biotech/pharma services (3), with a single healthcare analytics/software entry (Inovalon’s Keith Dunleavy, $4.6B).
Two family dynasties account for six of the fifteen slots: Medline (Charlie Mills, Andy Mills, Wendy Abrams) and Stryker (Ronda Stryker, John Brown, Jon Stryker).
Notable absences: no health insurers, no PBMs, no EHR vendors in the healthcare category, no digital health founders, no GLP-1 windfalls, no Regeneron or Moderna names.
Methodology matters: private companies valued on revenue/profit comps with a 10% liquidity discount; foundation money excluded; debt subtracted.
Takeaway for operators and investors: the durable healthcare fortunes come from physical assets, logistics, and consumables with decades-long compounding, not from the categories that dominate conference agendas and venture decks.
The list, in one breath
Forbes published its forty-fifth Forbes 400 on September 15, and Becker’s did the useful thing of pulling out the healthcare names so nobody has to scroll past the crypto guys and the Waltons. Fifteen people. Net worths frozen as of September 4. Add them up and you get somewhere around $136 billion, which is a lot of money until you remember that a single UnitedHealth Group earns more than that in revenue every five months or so and none of its executives are on this list. Sit with that for a second, because it is basically the whole essay.
Here is the roster, top to bottom, with Forbes 400 rank and net worth. Thomas Frist Jr. and family at 32 with $33.6 billion. Robert Duggan at 96 with $13.4 billion. Charlie Mills at 141 with $11 billion. Patrick Soon-Shiong at 151 with $10.3 billion. Li Ge at 156 with $10.1 billion. Carl Cook at 187 with $8.8 billion. Ronda Stryker at 241 with $7.1 billion. John Brown at 251 with $6.9 billion. Reinhold Schmieding at 293 with $5.8 billion. Andy Mills at 311 with $5.5 billion. Jon Stryker at 325 with $5.2 billion. Wendy Abrams and Stewart Rahr tied at 367 with $4.7 billion each. Keith Dunleavy and family at 375 with $4.6 billion. August Troendle bringing up the rear at 396 with $4.4 billion, which means one bad quarter for Medpace and he is off the list next year.
Read it once as a leaderboard and it is mildly interesting. Read it as a map of where value actually accumulates in American healthcare and it gets a lot more interesting, mostly because of what is not on it.
Fifteen names, four business models, zero surprises
Sort the fifteen by how they made the money and the pattern is almost comically clean. One hospital operator. Five people whose fortunes trace to distribution and supply, meaning Medline three times over, Kinray, and arguably Cook if you count the consumables side. Five device people, meaning three Stryker heirs and executives, Carl Cook, and Reinhold Schmieding at Arthrex. Three in the drug development ecosystem, two of whom own the picks and shovels rather than the drugs (Li Ge at Wuxi AppTec, August Troendle at Medpace) and one of whom, Duggan, is doing the purest long-shot biotech bet on the entire Forbes 400. Then Soon-Shiong, who is a category of one and always has been, and Dunleavy, who is the only person here whose company would be described as software without someone at the table objecting.
That is it. No payers. No PBMs. No pharma CEOs who inherited a company that already existed. No EHR founders in the healthcare bucket. No telehealth, no digital health, no value-based care platform founder, no AI scribe, no GLP-1 compounding pharmacy king, nothing that has been on the cover of a trade publication in the last five years. If your mental model of healthcare wealth was built from conference agendas and venture press releases, the Forbes 400 healthcare list is a cold shower.
The other pattern is time. Frist co-founded HCA in 1968. Medline was founded in 1966 and the family had been in the business since 1910 as a garment and apron maker. Stryker dates to 1941. Cook to 1963. Kinray to 1944. Arthrex to 1981. Medpace to 1992. Even the youngest fortunes on the list, Summit and Inovalon, involve people who were already wealthy from previous decades-long runs (Duggan from Pharmacyclics, Dunleavy from building Inovalon over more than 20 years). The median founding year of the underlying company is somewhere in the 1960s. Healthcare wealth, at the ten-figure level, is mostly a story about compounding over 40 to 60 years in a business that touches physical product or physical patients and does not get disrupted because nobody with a Series A wants to run a warehouse in Mundelein, Illinois.
Hospitals: the Frist family and the unfashionable genius of owning beds
Tom Frist Jr. sits at the top of the healthcare list and 32nd overall with $33.6 billion, which is more than the next two names combined. He was an Air Force flight surgeon who co-founded HCA with his father, Thomas Frist Sr., and Jack Massey in Nashville in 1968. The Massey part is the fun trivia: he was the Kentucky Fried Chicken guy, which explains why HCA was built from day one as a scalable, replicable, franchise-minded operation rather than a mission-driven community institution.
HCA went public, went private in a 1989 leveraged buyout, went public again, went private again in the 2006 KKR and Bain LBO that was the largest in history at the time at roughly $33 billion, and went public a third time in 2011. Every one of those cycles was an opportunity for the Frist family to reload, and they took every one.
Today HCA runs roughly 190 hospitals and around 2,500 sites of care, throws off something north of $75.6 billion in annual revenue, and is the single most efficient large hospital operator in the country by essentially any margin metric you care to pull. The reason the Frist fortune is so large is not that hospitals are a great business. Most hospitals are a terrible business. It is that HCA figured out, decades before anyone else, that the hospital business is a real estate, labor scheduling, supply chain, and payer contracting business that happens to have surgeons in it. Density in a market gets you leverage with Blue Cross. Scale in purchasing gets you leverage with Medline (see below, the circle of life). Standardized staffing models get you labor cost per adjusted admission that nonprofits cannot touch. Frist Jr. was CEO through most of that, and the family remains a top holder.
Worth noting for the policy wonks reading this: Frist’s brother Bill was Senate Majority Leader, and HCA paid what was then the largest healthcare fraud settlement in history, around $1.7 billion in 2000 and 2003, over Medicare billing practices. None of that dented the compounding. If anything it is a reminder that a fine of $1.7 billion against an enterprise generating hundreds of billions in cumulative revenue is a cost of doing business, and the market priced it that way. The HCA story is the cleanest case study on this list of a thesis that every operator should internalize: in a fragmented, low-margin, regulated industry, the person who standardizes and scales the boring parts ends up owning the whole thing.
Distribution: Medline, Kinray, and the boring middle that eats everyone’s lunch
Five of fifteen slots go to people whose money came from moving boxes. Three of them share one company. Charlie Mills at $11 billion, Andy Mills at $5.5 billion, and Wendy Abrams at $4.7 billion are all Medline, the now publicly traded Northfield, Illinois medical supply behemoth that Jim and Jon Mills founded in 1966 after the family had been sewing hospital gowns and aprons since 1910. Combined, the three cousins are worth about $21 billion on this list alone, and there are other family members who did not clear the Forbes 400 cutoff but are not exactly hurting.
Medline is the company that nobody outside the industry has heard of and everybody inside the industry buys from. Something on the order of $28.4 billion plus in annual revenue, more than 300,000 SKUs, its own manufacturing for a huge share of what it sells, and a distribution footprint that reaches basically every hospital, surgery center, nursing home, and physician office in the country. In 2021, Blackstone, Carlyle, and Hellman & Friedman bought a majority stake in a deal valued around $34 billion, one of the largest LBOs ever, and the Mills family rolled a big chunk of equity. Medline then went public in December 2025 in what ended up being the largest IPO of 2025 globally and the largest healthcare IPO ever, raising about $6.26 billion in its debut and about $6.3 billion including overallotments. That IPO is a large part of why three Medline names are on the list at these levels this year. The liquidity discount came off.
The structural insight here is one that gets underweighted by every founder who wants to build software for hospitals. Medline’s moat is not technology. It is being the low-cost, vertically integrated, everything-store for consumables, with a sales force that is in the building every week and a private-label catalog that lets it undercut Cardinal, McKesson, and Owens & Minor on the products that actually move. Hospitals hate switching suppliers because the nursing staff knows where the gauze is. That is the whole moat. It has held for 60 years and it is worth $21 billion to three cousins.
Stewart Rahr is the other distribution name, at $4.7 billion, and his story is the one everybody should study as a case in knowing when to sell. His father started Kinray in 1944 as a pharmaceutical wholesaler in Queens serving independent pharmacies in the New York metro. Rahr took it from a regional player to the largest privately held drug distributor in the country, then sold it to Cardinal Health in 2010 for $1.3 billion in cash. That was 16 years ago. He has been on the Forbes 400 every year since, and his net worth has grown, not shrunk, because a guy who sells a distribution business for $1.3 billion in cash at the top of the independent pharmacy cycle and then invests it for 16 years does fine. The pharmacy wholesale business he left has since been ground down to three national players with operating margins measured in basis points. Rahr got out at the exact moment when scale became the only thing that mattered and he was not going to be the one with the scale. Respect.
Devices: Stryker, Cook, Arthrex, and the compounding power of a titanium screw
The device contingent is the largest single bucket, and the Stryker family alone takes three slots. Ronda Stryker at $7.1 billion, Jon Stryker at $5.2 billion, and John Brown at $6.9 billion. The first two are grandchildren of Homer Stryker, the Kalamazoo orthopedic surgeon who invented a mobile hospital bed and a cast-cutting saw and founded the company in 1941. The third, Brown, is the professional CEO who ran Stryker from 1977 to 2003 and stayed as chairman until 2009, and whose equity from that run is now worth almost seven billion dollars.
Stryker did about $25.1 billion in sales in 2025 and has compounded revenue and earnings at a rate that made Brown famous for a simple 20 percent annual earnings growth target that the company hit for something like 28 straight years.
The thing to understand about Stryker’s fortune, and about ortho devices generally, is that the whole category is a razor-and-blades business dressed up in a surgeon’s coat. You place robots (Mako) and capital equipment in the OR, you lock in the implant stream, and every hip and knee that goes in for the next decade comes with a Stryker part number. Aging population, rising obesity, more joints per capita, higher-priced implants per joint, and pricing power that hospitals have never been able to crack because the surgeon picks the implant and the surgeon does not pay for it. The three Stryker names on this list are worth about $19 billion combined, and the company’s market cap is a multiple of that, which tells you how much of that value is now in the hands of index funds and pension plans rather than the founding family.
Carl Cook at $8.8 billion is the private version of the same story. Cook Group, out of Bloomington, Indiana, was started by Bill Cook in 1963 in a spare bedroom making wire guides and catheters for interventional procedures. It is still privately held, still family owned, and is the largest privately held medical device company in the world with revenue somewhere in the low billions. Carl took over as CEO when his father died in 2011. Cook is a mostly consumables business, meaning stents, catheters, guidewires, needles, the stuff that gets used once and thrown away, which is the best kind of device business because the recurring revenue is baked into the procedure rather than into a service contract. It also means Cook’s $8.8 billion is being valued by Forbes on a private comp with a 10 percent haircut, so the real number is arguably higher.
Reinhold Schmieding at $5.8 billion is the one that ortho people find most interesting. He founded Arthrex in Munich in 1981 and moved it to Naples, Florida, where it has stayed privately held and where Schmieding has been notoriously allergic to outside capital, public markets, and anything that would require him to explain himself to a board. Arthrex is the sports medicine and arthroscopy category leader, with revenue estimated north of $3 billion, and it has been growing faster than Stryker, Zimmer, or Smith and Nephew in its lanes for a long time. The company is famous inside the industry for a couple of things: an enormous surgeon education machine that trains tens of thousands of orthopedic surgeons a year in Arthrex techniques on Arthrex equipment, and a product development cadence that produces hundreds of new SKUs annually. That surgeon training flywheel is the real business. Train the fellow on your anchor, and the fellow uses your anchor for 30 years.
Put the five device fortunes together and they total about $34 billion, roughly equal to Frist alone. Every one of them is built on the same three-part engine: a procedure that is growing with demographics, a consumable or implant that rides along with the procedure, and a clinician relationship that is stickier than any enterprise software contract ever signed.
Biotech and the picks-and-shovels crowd: Duggan, Soon-Shiong, Li Ge, Troendle
Robert Duggan at $13.4 billion is the second-richest person on the healthcare list and the most interesting story on it, because his money is almost entirely a function of one stock, Summit Therapeutics, and the fate of one drug, ivonescimab. Duggan is a Scientology-affiliated serial investor who had already made billions as the largest shareholder and CEO of Pharmacyclics when AbbVie bought it for $21 billion in 2015 on the strength of Imbruvica. He then put $63 million into a failing British antibiotic company called Summit in 2020, installed himself as co-CEO, and in late 2022 licensed the Western rights to ivonescimab, a PD-1 and VEGF bispecific antibody, from China’s Akeso for $500 million upfront and up to $5 billion in milestones. The HARMONi-2 trial in China showed ivonescimab beating Keytruda head to head in first-line PD-L1 positive non-small cell lung cancer, which is the single most valuable pharma franchise on earth and Merck’s entire near-term future. Summit’s stock went vertical. Duggan owns on the order of four-fifths of it.
The essay could stop there, but the nuance is important for the biotech crowd. Summit still has not secured an FDA approval; instead, the company submitted a Biologics License Application in late 2025 based on the global Phase III HARMONi trial, and in January 2026 the FDA accepted the filing and set a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026. Updated analyses presented through mid‑2026 have shown progressively stronger overall survival signals in both Western and Asian patient subgroups compared with earlier cuts, but the label, if approved, will be for EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC after third‑generation EGFR TKI therapy, not for the Keytruda-dominated first‑line PD‑L1 positive population. The entire valuation now rests on whether a Chinese‑origin bispecific can win in the U.S. regulatory and commercial environment at the exact moment Washington is trying to build a wall around Chinese biotech. Duggan’s $13.4 billion is real on paper and extremely volatile. He is also 82 years old and controls a company that is the single largest test case of the China‑to‑US licensing pipeline that has reshaped pharma business development over the last three years. If ivonescimab wins in its initial EGFR‑mutant indication and expands beyond it, this list looks very different next year. If it does not, Duggan drops several hundred spots and Summit becomes a case study in a different kind of textbook.
Patrick Soon-Shiong at $10.3 billion is the only person on the list who is a practicing physician turned drug inventor turned serial founder turned newspaper owner. He developed Abraxane, the albumin-bound paclitaxel that became a pancreatic cancer standard, and sold Abraxis to Celgene for $2.9 billion in 2010, having earlier sold American Pharmaceutical Partners for a similar sum. That is the money. Everything since has been an attempt to do it again, most recently through ImmunityBio, which got Anktiva approved for non-muscle invasive bladder cancer in 2024 after a rough regulatory road. He also owns the Los Angeles Times, which has been an expensive hobby. His net worth is a useful reminder that in biotech the fortune is made at the exit, not at the science, and that a single drug formulation improvement in an old generic can be worth more than a dozen novel mechanisms that never make it through Phase 3.
Li Ge at $10.1 billion is the entry that will raise the most eyebrows for the policy audience. He is chairman and CEO of Wuxi AppTec, the Chinese contract research, development, and manufacturing giant that does discovery, preclinical, clinical trial support, and API manufacturing for essentially every large pharma and a huge share of US biotechs. He is on the Forbes 400, a list of the richest Americans, because he is a US citizen who did his PhD at Columbia and co-founded Wuxi in Shanghai in 2000.
Wuxi is also the primary target of the BIOSECURE Act, the effort in Congress to bar federal funds and federally funded entities from contracting with named Chinese biotech companies of concern. The bill has been through several iterations, and the industry has spent three years scrambling to understand what onshoring drug development away from Wuxi would cost and how long it would take. The answer is: a lot, and a long time. That is why Li Ge is still on this list. The picks and shovels of drug development are disproportionately made in China, and no amount of legislation has yet changed that fact on the ground.
August Troendle at $4.4 billion is the American picks-and-shovels version. He founded Medpace in Cincinnati in 1992, took it public in 2016, and still owns roughly a fifth of it as CEO. Medpace is a full-service CRO that has quietly outgrown its larger and more famous competitors over the last few years by focusing on small and mid-size biotech sponsors and running trials with a fully in-house model rather than the outsourced-everything approach of the big CROs. Troendle is a physician who spent time at the FDA and at Sandoz before starting the company, and he is one of the few CRO founders still running the company he built. His position at 396 is precarious in the sense that Medpace’s stock is tightly correlated to biotech funding cycles and he is worth about $200 million more than the cutoff, but the underlying business is a monument to a simple idea: when 3,000 biotechs raise money to run trials, sell them the trial.
The lone software guy: Keith Dunleavy and Inovalon
Keith Dunleavy and family come in at 375 with $4.6 billion, and Dunleavy is the only person on the entire healthcare list whose company is fundamentally a data and software business. He is a physician who built Inovalon, originally MedAssurant, in Bowie, Maryland starting in 1998, focused on risk adjustment, quality analytics, and the data plumbing that Medicare Advantage plans and providers use to document risk scores and quality measures. Inovalon went public in 2015 in one of the largest healthcare IT IPOs ever, acquired Ability Network in 2018 for $1.2 billion to get a provider-facing footprint, and was taken private in 2021 by a Nordic Capital-led consortium including Insight Partners and 22C Capital in a deal valued at $7.3 billion. Dunleavy rolled equity and stayed on as CEO.
The reason this matters for the health tech audience is that Dunleavy’s fortune is a clean illustration of both the ceiling and the path for healthcare software wealth. The ceiling: after 28 years of building, a public listing, a major acquisition, and a take-private at a healthy multiple, the founder of one of the most successful healthcare data companies in history is worth $4.6 billion, which puts him behind the grandchildren of a guy who invented a hospital bed. The path: the money was made in risk adjustment and quality measurement, meaning the software that sits on top of the Medicare Advantage payment mechanism and helps plans get paid. It was not made on consumer engagement, or interoperability, or clinical decision support, or any of the things that dominate health tech pitch decks. It was made in the plumbing that determines who gets paid how much by CMS. That is where the money has always been in healthcare software, and it is the business model that every risk adjustment vendor, every clinical documentation company, and every ambient scribe with a coding upsell is, whether they admit it or not, trying to replicate.
Who is missing, and why that matters more than who is on it
Now the fun part. Go through the categories that generate the most headlines, the most venture dollars, and the most policy fights in healthcare, and check them against this list.
Health insurance. UnitedHealth, Elevance, CVS Aetna, Cigna, Humana, Centene, and Molina collectively run well over a trillion dollars of annual revenue through their books. Not a single executive, founder, or heir from any of them is on the Forbes 400 healthcare list. The reason is structural and important. These are companies that were built by public shareholders and professional managers, with founding equity long since dispersed. The wealth is real and enormous, but it is spread across index funds and the compensation of a long line of CEOs who each got rich but not Forbes 400 rich. The largest healthcare companies in America have produced zero billionaires at the top of the list, and the reason is that the money in managed care is captured by the corporate entity and its shareholders, not by any individual with a founding stake.
PBMs. Same story, more so. Three companies control something like 80 percent of claims. They are all subsidiaries of the payers above. There is no PBM billionaire because there is no PBM founder left standing.
Pharma. Merck, Pfizer, Lilly, J&J, AbbVie, Bristol, Amgen, Gilead. The list is silent. The Lilly family foundations own a meaningful stake in Eli Lilly and the GLP-1 boom has made Lilly the most valuable healthcare company on earth, but foundation money is excluded from the Forbes methodology and the individual Lilly heirs are scattered across trusts. The founders of the pharma majors died a century ago. The only pharma-adjacent names on the list are a formulation inventor (Soon-Shiong), a biotech gambler (Duggan), and two service providers (Li Ge, Troendle). Regeneron’s Len Schleifer and George Yancopoulos, who have been on this list in prior years, do not appear in Becker’s 15 this year, which is a function of Regeneron’s stock retreating from its peak and the founders’ stakes falling below the cutoff. Moderna’s Stéphane Bancel and the Flagship cohort, who were all over the list in 2021 and 2022, are gone.
EHRs and health IT. Judy Faulkner of Epic is a perennial Forbes 400 member with a net worth in the high single digit billions, and she is not in Becker’s 15. Neal Patterson of Cerner passed in 2017. Faulkner’s absence is almost certainly a classification artifact, since Forbes tends to slot her under technology rather than healthcare, but the practical effect is that the largest healthcare software company in the world by clinical footprint does not show up in the healthcare category. Either way, one name. Health IT as a sector has produced fewer ten-figure founder fortunes in 50 years than the Stryker family produced from a cast-cutting saw.
Digital health and venture-backed everything. Zero. Not one founder from the roughly $100 billion of venture capital deployed into digital health since 2015 is on this list. Not Livongo (Glen Tullman did very well but not this well), not Teladoc, not Oscar, not Hims, not Doximity, not GoodRx. The wave of digital health SPACs and IPOs in 2020 and 2021 produced a lot of paper billionaires for about 18 months and then produced a lot of lessons. The single closest thing to a venture-style outcome on the list is Duggan, and he is a concentrated public-market bettor, not a founder-operator building a product.
Hospitals beyond HCA. The Frist family is the only hospital fortune. Tenet, CHS, UHS, LifePoint, and the entire nonprofit sector are absent, the last for obvious reasons. The Miller family at UHS has been on the list in prior years and is not in Becker’s 15 this year. Hospital operations are so hard that only one company in the history of the sector has produced generational wealth at this scale, and that company did it through three LBOs and a KFC co-founder.
The absences tell you more than the presences. Healthcare’s largest, most politically contested, most venture-funded, and most technologically ambitious sectors have produced almost no individual fortunes at the Forbes 400 level. The fortunes are in gauze, catheters, hip implants, hospital beds, pharmacy wholesale, and contract research. The industry’s money is real, but it is captured by corporate shareholders in payers and pharma, and by families in distribution and devices, and almost never by the people whose LinkedIn headlines say founder.
The methodology footnote nobody reads but everybody should
Forbes describes its process as interviews with list members, employees, asset managers, attorneys, peers, and rivals, plus SEC filings, court records, and news. Public stakes get marked to market as of September 4. Private companies get valued on revenue or profit estimates against comparable public companies, with a 10 percent liquidity discount. Debt is subtracted. Money in charitable foundations is excluded.
Three implications for reading the healthcare list. First, the private company names, meaning Cook, Arthrex, and until recently Medline, are almost certainly undervalued relative to what a strategic buyer would pay. A 10 percent haircut on a category-leading device company with no debt and 40 years of growth is generous to the buyer. Carl Cook and Reinhold Schmieding are probably worth more than the list says.
Second, the foundation exclusion is doing serious work in pharma. The Lilly Endowment alone holds a stake in Eli Lilly worth tens of billions of dollars, and the GLP-1 run has made it one of the largest foundations in the world. None of that shows up as an individual fortune because it is legally not one. Same with the Stryker family’s philanthropic vehicles and Jon Stryker’s Arcus Foundation. The list measures private wealth, not wealth created, and in healthcare the gap between those two numbers is unusually large.
Third, the September 4 snapshot date means Duggan’s number is a point-in-time bet on Summit’s stock price, and Summit’s stock moves 20 percent on a trial readout. The healthcare list is unusually sensitive to a handful of binary events in a way that the retail or tech lists are not. Between Summit’s regulatory path, Medpace’s exposure to biotech funding, and Wuxi’s exposure to BIOSECURE, roughly $28 billion of the $136 billion on this list is subject to events that could resolve in either direction within 12 months.
What this means if you build, invest, or sell in healthcare
Three practical conclusions, none of them comfortable for people who make a living on the innovation side of the industry.
One: the compounding assets in healthcare are physical, sticky, and slow. Consumables that ride along with procedures. Implants chosen by clinicians who do not pay for them. Distribution relationships that are annoying to change. Beds in the right zip codes. The Forbes 400 healthcare list is 15 people who mostly own things that get used up and reordered, or things that are surgically installed and cannot be swapped out for a competitor’s product. If a business does not have one of those properties, the founder should expect a good outcome, not a generational one, and should plan accordingly. Dunleavy’s $4.6 billion after 28 years of Inovalon is the realistic ceiling for a healthcare software founder who does everything right. That is a wonderful outcome. It is also about the same as one Medline cousin.
Two: the picks and shovels of drug development are a better business than the drugs. Li Ge and Troendle together are worth $14.5 billion for selling services to people who are betting on molecules. Duggan and Soon-Shiong together are worth $23.7 billion for betting on molecules, but only one of them has a realized win and the other’s fortune could halve on a single FDA letter. For an investor, the risk-adjusted lesson is obvious and has been obvious since the Gold Rush. For a policy audience, the lesson is that a US citizen running a Chinese CDMO is one of the richest people in American healthcare, which is a more honest statement about the supply chain than anything in the BIOSECURE hearing record.
Three: the categories with the most political heat produce the least individual wealth, and that is not a coincidence. Payers and PBMs are attacked in Congress every month for being too profitable, and they are profitable, but the profit accrues to a corporate entity with a dispersed shareholder base and a rotating cast of CEOs. There is no UnitedHealth family. There is a Frist family, a Mills family, a Stryker family, a Cook family. The billionaires are in the parts of the industry that nobody holds a hearing about, because gauze and hip implants and pharmacy wholesale are not politically legible. The next time someone in a policy conversation says the money in healthcare is in insurance, the correct response is that the money in insurance is in insurance company stock, and the money that becomes a person’s money is in a warehouse in Illinois.
Fifteen names. About $136 billion. One hospital chain, three cousins with a catalog, three heirs to a cast saw, a guy who sold a drug wholesaler at exactly the right moment, a few device founders who never took outside money, two service providers to the pharma industry, one bispecific bet, one formulation chemist, and one risk adjustment platform. That is what healthcare wealth looks like in 2026, and it looks almost exactly like it did in 2006. The industry has spent two decades and a few hundred billion dollars in venture and growth capital trying to change that, and the list is a polite way of saying it has not worked yet
.